8-K 1 oncx_8k.htm FORM 8-K oncx_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 2, 2019

 

Oncolix, Inc.

(Exact name of registrant as specified in its charter)

 

Florida

 

333-192405

 

46-3046340

(state or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

 

14405 Walters Road, Suite 780

Houston, TX

 

77014

(address of principal executive offices)

 

(zip code)

 

281-402-3167

(registrant’s telephone number, including area code)

 

___________________________________________

(former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 
 
 

 

Item 8.01 Other Events

 

On July 2, 2019, the Company received a final notice of default under its license agreement for CycloSam, its product candidate. The default references milestones required under the license agreement.

 

As previously disclosed, the Company has been unable to finance its continuing operations and can no longer meet its continuing obligations. Substantially all of its remaining assets are pledged to the holders of its convertible notes.

 
 

2

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Oncolix, Inc.

 

 

 

 

Dated: July 3, 2019

 

/s/ Michael T. Redman

 

 

 

Michael T. Redman

 

 

 

Chief Executive Officer

 

 

 

3